Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.

Date publication

janvier 2021

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr HENNEQUIN Audrey

Tous les auteurs :
Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Lerebours F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33561617

Résumé

Among metastatic breast cancer (MBC) patients, those with a triple-negative breast cancer phenotype (mTNBC) have the worst prognosis, but the benefit of chemotherapy beyond second line on outcome remains uncertain. The purpose of this study was to identify predictive factors of outcome after third- or fourth-line chemotherapy.

Mots clés

Chemotherapy, Heavily pretreated, Metastatic breast cancer, Prognostic factors, Real-life

Référence

Breast. 2021 Jan 30;56:18-25